Who
Raju Prasad
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, CRISPR Therapeutics AG.
In numbers
- Trades disclosed
- 71
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $10.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Mar 2023
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code G | —750 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code G | —750 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 23 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $173K3,708 at $46.78 | filing |
| 23 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $173K3,708 at $46.78 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —6,250 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —38,499 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —38,499 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,250 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,250 | filing |
| 20 Mar 2026filed 24 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —6,250 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $282K5,848 at $48.26 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $194K4,021 at $48.26 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code G | —750 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $282K5,848 at $48.26 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Sold | $194K4,021 at $48.26 | filing |
| 16 Mar 2026filed 17 Mar 2026 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code G | —750 at $0.00 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name Raju Prasad; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.